By Next Move Strategy Consulting Next Move Strategy Consulting reports that the global Infectious Disease Diagnostics Market is projected to reach around USD 35 billion by 2030, expanding at a CAGR of approximately 10% from 2024 to 2030.
|
By DPI Research The global AI in biotechnology market was valued at USD 3.23 billion in 2024, and is expected to reach USD 14.97 billion by 2033, rising at a CAGR of 21.1% during the forecast period.
|
By Manhattan BioSolutions, Inc. Collaborative research between Manhattan BioSolutions and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University will advance next-generation ADC platform using novel TxD payloads
|
By NEXS Technology Group NEXS Technology Group is excited to announce its acceptance into the prestigious AWS Startup Program, a significant milestone that will propel the development and deployment of CancerScope-AI, our state-of-the-art artificial intelligence tool.
|
By NEXS BioMedica Corporation NEXS BioMedica, a forward-thinking biotech pharmaceutical company, proudly introduces CancerScope-AI, an innovative artificial intelligence system set to transform the battle against rare cancers.
|
By Manhattan BioSolutions, Inc. Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, today announced that its RNA-targeting therapeutic, MABS-139, will be evaluated in...
|
By Maxis Clinical Sciences New Global Centre to Advance Clinical Research and Digital Innovation
|
By Manhattan BioSolutions, Inc. Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative precision biologics, today announced its selection as an awardee of the Science in the City QuickFire Challenge launched by Johnson & Johnson...
|
